Mutations in IDH1/2 occur frequently in acute myeloid leukemia (AML) and gliomas and are neomorphic mutations that lead to the aberrant production of 2-hydroxyglutarate (2-HG) while consuming NADPH (122). Here, IDH1 is linked to central nervous system cancer.